You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Discovery of Novel Drugs for Autism

    SBC: ASDDR, LLC            Topic: 101

    Summary The goal of this study is to discover novelmechanism based pharmacological intervention for autisma devastating neurodevelopmental disorder with no treatment currentlyGenetic sequencing has revealed extensive overlap in risk genes for autism and for cancermany of which are chromatin remodeling factors important for transcriptional regulationsuggesting the possibility of repurposing the ant ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  2. Preclinical Development of a Novel Small Molecule Drug for Sepsis

    SBC: THERASOURCE, LLC            Topic: 300

    PROJECT DESCRIPTIONThis STTR Phase I proposal is intended to demonstrate the feasibility of developing tanshinone small molecule analogTSAas an effective and safe small molecule therapy for patients with sepsis and septic shockIn the USmore than one million people develop sepsis every yearYetno effective anti sepsis treatment exists other than antibiotics and supportive careWe have discovered that ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  3. HLS Cyclic CAR peptide a targeted therapy for pulmonary hypertension

    SBC: VASCULAR BIOSCIENCES, INC.            Topic: NHLBI

    PUBLIC ABSTRACT This project in response to announcement HLS describes a development program for CARSKNKDC CAR a synthetic cyclic peptide that selectively targets diseased pulmonary vascular endothelium and enhances the therapeutic effect of vasodilator therapies for the treatment of pulmonary hypertension PH PH is a disorder of elevated pulmonary vascular resistance characterized by ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  4. Developing Heparan Sulfate Glycan Array

    SBC: GLYCAN THERAPEUTICS CORPORATION            Topic: NIGMS

    Project titleDeveloping heparan sulfate glycan array This proposal is aimed at developing a high throughput method to study the interactions between heparan sulfateHSand proteinsHS is a highly sulfated polysaccharide displaying a wide range of biological functionsGlycan Therapeutics is a company specialized in HS related research productsIn this proposalan HS array technique will be constructed us ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Development of a POEGMA Aptamer rapid onset anticoagulant that eliminates antigenicity to anti PEG antibodies

    SBC: Gateway Bio, Inc.            Topic: NHLBI

    ABSTRACT The objective of this STTR proposal is to reformulate a promising PEG aptamer rapid onset anticoagulant ROA by applying a novel PEG like POEGMA polymer brush technology capable of eliminating anti PEG antigenicity The importance of this proposal is highlighted by the early termination of a recent Phase III clinical trial of the original PEG aptamer conjugate in which severe allergic ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Developing a new therapeutic agent for retinal ciliopathies

    SBC: Rescindo Therapeutics Inc            Topic: N

    The ciliopathies are a group of andgt overlapping clinical disorders caused by defects in the primary cilium and its anchoring structure the basal body Although individually rare this group contributes significantly to the population genetic disease burden with some estimates placing their combined incidence to as much as Importantly although some ciliopathies are lethal most pat ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  7. High throughput CRISPR Cas cell line generation using the CellRaft Array platform

    SBC: CELL MICROSYSTEMS INC            Topic: NHGRI

    Project Summary Genome editing technologies such CRISPR Cas provide a rapid and targeted means of both knocking out gene expression and knocking in gene modifications However the current workflow required for CRISPR cell line generation relies on several technologies which reduce throughput efficiency and the overall viability of genome edited cells Cell Microsystems has developed a single ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  8. A novel product for tendinopathy treatment

    SBC: NEW YORK R & D CENTER FOR TRANSLATIONAL MEDICINE & THERAPEUTICS INC            Topic: NIA

    Project Summary This study aims to prove the concept and feasibility that TendonCure extracellular vesicles that contain signaling molecules i e exosomes secreted by mesenchymal stem cells i e tendon stem progenitor cells TSPCs or adipose derived stem cells ADSCs from individual patients donors cultured on a novel scaffold exert therapeutic efficacy on tendinopathy when injected into ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  9. Novel Small Molecule Macrophage Inhibitors for the Treatment of Retinal Diseases

    SBC: Eyedesis Biosciences, LLC            Topic: N

    PROJECT SUMMARY ABSTRACT Persistent disease activity PDA in spite of anti vascular endothelial growth factor VEGF therapy remains a significant clinical unmet need for patients with neovascular age related macular degeneration NVAMD The purpose of this STTR Phase I grant application is to develop novel therapies that will be effective for the treatment of PDA associated with NVAMD The cu ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Personalized Neural Stem Cell Therapy for Cancer

    SBC: Falcon Therapeutics, Inc.            Topic: NCATS

    Project Summary Abstract Glioblastoma GBM is the most common primary brain tumor and one of the deadliest forms of cancer Standard surgery chemotherapy and radiation fail to eliminate the infiltrative invasive cancer cells Median survival remains only months Drugs that seek out the disseminated GBM cells behind the blood brain barrier will prevent the inevitable recurrence in patients ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government